Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)

 

Safety and tolerability of nintedanib in patients with autoimmune disease-related interstitial lung diseases (ILDs) in subgroups by sex and age

Hoffmann-Vold AM et al.
 

Acceder

 

SC-ES-09814

¿Te ha resultado útil esta información?